Patents by Inventor Robin E. Harkness

Robin E. Harkness has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7241449
    Abstract: Purified and isolated nucleic acid molecules are provided which encode Tbp2 proteins of M. catarrhalis strains M35, 3 and LES1. The nucleic acid sequence may be used to produce recombinant Tbp2 proteins of the strain of Moraxella free of other proteins of the Moraxella strain for purposes of diagnostics and medical treatment. Furthermore, the nucleic acid molecules may be used in the diagnosis of infection.
    Type: Grant
    Filed: April 12, 1999
    Date of Patent: July 10, 2007
    Assignee: Aventis Pasteur Limited
    Inventors: Lisa E. Myers, Anthony B. Schryvers, Robin E. Harkness, Sheena M. Loosmore, Run-Pan Du, Yan-Ping Yang, Michel H. Klein
  • Patent number: 7118749
    Abstract: Purified and isolated nucleic acid is provided which encodes a transferrin receptor protein of a strain of Haemophilus or a fragment or an analog of the transferrin receptor protein. The nucleic acid sequence may be used to produce peptides free of contaminants derived from bacteria normally containing the Tbp1 or Tbp2 proteins for purposes of diagnostics and medical treatment. Furthermore, the nucleic acid molecule may be used in the diagnosis of infection. Also provided are recombinant Tbp1 or Tbp2 and methods for purification of the same. Live vectors expressing epitopes of transferrin receptor protein for vaccination are provided.
    Type: Grant
    Filed: January 14, 2002
    Date of Patent: October 10, 2006
    Assignee: Connaught Laboratories Limited
    Inventors: Sheena M. Loosmore, Robin E. Harkness, Anthony B. Schryvers, Pele Chong, Scott Gray-Owen, Yan-Ping Yang, Andrew D. Murdin, Michel H. Klein
  • Publication number: 20030170657
    Abstract: An isolated and purified outer membrane protein of a Moraxella strain, particularly M. catarrhalis, having a molecular mass of about 200 kDa, is provided. The about 200 kDa outer membrane protein as well as nucleic acid molecules encoding the same are useful in diagnostic applications and immunogenic compositions, particularly for in vivo administration to a host to confer protection against disease caused by a bacterial pathogen that produces the about 200 kDa outer membrane protein or produces a protein capable of inducing antibodies in a host specifically reactive with the about 200 kDa outer membrane protein.
    Type: Application
    Filed: June 20, 2002
    Publication date: September 11, 2003
    Inventors: Ken Sasaki, Robin E. Harkness, Sheena M. Loosmore, Pele Chong, Michel H. Klein
  • Publication number: 20030171254
    Abstract: An isolated and purified outer membrane protein of a Moraxella strain, particularly M. catarrhalis, having a molecular mass of about 200 kDa, is provided. The about 200 kDa outer membrane protein as well as nucleic acid molecules encoding the same are useful in diagnostic applications and immunogenic compositions, particularly for in vivo administration to a host to confer protection against disease caused by a bacterial pathogen that produces the about 200 kDa outer membrane protein or produces a protein capable of inducing antibodies in a host specifically reactive with the about 200 kDa outer membrane protein.
    Type: Application
    Filed: June 20, 2002
    Publication date: September 11, 2003
    Inventors: Ken Sasaki, Robin E. Harkness, Sheena M. Loosmore, Pele Chong, Michel H. Klein
  • Publication number: 20030088086
    Abstract: Purified and isolated nucleic acid is provided which encodes a transferrin receptor protein of a strain of Haemophilus or a fragment or an analog of the transferrin receptor protein. The nucleic acid sequence may be used to produce peptides free of contaminants derived from bacteria normally containing the Tbp1 or Tbp2 proteins for purposes of diagnostics and medical treatment. Furthermore, the nucleic acid molecule may be used in the diagnosis of infection. Also provided are recombinant Tbp1 or Tbp2 and methods for purification of the same. Live vectors expressing epitopes of transferrin receptor protein for vaccination are provided.
    Type: Application
    Filed: January 14, 2002
    Publication date: May 8, 2003
    Inventors: Sheena M. Loosmore, Robin E. Harkness, Anthony B. Schryvers, Pele Chong, Scott Gray-Owen, Yan-Ping Yang, Andrew D. Murdin, Michel H. Klein
  • Patent number: 6448386
    Abstract: An isolated and purified outer membrane protein of a Moraxella strain, particularly M. catarrhalis, having a molecular mass of about 200 kDa, is provided. The about 200 kDa outer membrane protein as well as nucleic acid molecules encoding the same are useful in diagnostic applications and immunogenic compositions, particularly for in vivo administration to a host to confer protection against disease caused by a bacterial pathogen that produces the about 200 kDa outer membrane protein or produces a protein capable of inducing antibodies in a host specifically reactive with the about 200 kDa outer membrane protein.
    Type: Grant
    Filed: March 19, 1998
    Date of Patent: September 10, 2002
    Assignee: Aventis Pasteur Limited
    Inventors: Ken Sasaki, Robin E. Harkness, Sheena M. Loosmore, Pele Chong, Michel H. Klein
  • Patent number: 6440701
    Abstract: Purified and isolated nucleic acid molecules are provided which encode transferrin receptor proteins of Moraxella, such as M. catarrhalis or a fragment or an analog of the transferrin receptor protein. The nucleic acid sequence may be used to produce recombinant transferrin receptor proteins Tbp1 and Tbp2 of the strain of Moraxella free of other proteins of the Moraxella strain for purposes of diagnostics and medical treatment. Furthermore, the nucleic acid molecule may be used in the diagnosis of infection.
    Type: Grant
    Filed: April 14, 1998
    Date of Patent: August 27, 2002
    Assignee: Aventis Pasteur Limited
    Inventors: Lisa E. Myers, Anthony B. Schryvers, Robin E. Harkness, Sheena M. Loosmore, Run-Pan Du, Yan-Ping Yang, Michel H. Klein
  • Patent number: 6440424
    Abstract: An isolated and purified outer membrane protein of a Moraxella strain, particularly M. catarrhalis, has a molecular mass of about 200 kDa. The about 200 kDa outer membrane protein as well as nucleic acid molecules encoding the same are useful in diagnostic applications and immunogenic compositions, particularly for in vivo administration to a host to confer protection against disease caused by a bacterial pathogen that produces the about 200 kDa outer membrane protein or produces a protein capable of inducing antibodies in a host specifically reactive with the about 200 kDa outer membrane protein.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: August 27, 2002
    Assignee: Aventis Pasteur Limited
    Inventors: Ken Sasaki, Robin E. Harkness, Sheena M. Loosmore, Michel H. Klein
  • Patent number: 6440425
    Abstract: An isolated and purified outer membrane protein of a Moraxella strain, particularly M. catarrhalis, having a molecular mass of about 200 kDa, is provided. The about 200 kDa outer membrane protein as well as nucleic acid molecules encoding the same are useful in diagnostic applications and immunogenic compositions, particularly for in vivo administration to a host to confer protection against disease caused by a bacterial pathogen that produces the about 200 kDa outer membrane protein or produces a protein capable of inducing antibodies in a host specifically reactive with the about 200 kDa outer membrane protein.
    Type: Grant
    Filed: March 26, 1996
    Date of Patent: August 27, 2002
    Assignee: Aventis Pasteur Limited
    Inventors: Ken Sasaki, Robin E. Harkness, Sheena M. Loosmore, Pele Chong, Michel H. Klein
  • Patent number: 6437096
    Abstract: Purified and isolated nucleic acid molecules are provided which encode transferrin receptor proteins of Moraxella, such as M. catarrhalis or a fragment or an analog of the transferrin receptor protein. The nucleic acid sequence may be used to produce recombinant transferrin receptor proteins Tbp1 and Tbp2 of the strain of Moraxella free of other proteins of the Moraxella strain for purposes of diagnostics and medical treatment. Furthermore, the nucleic acid molecule may be used in the diagnosis of infection.
    Type: Grant
    Filed: January 3, 1997
    Date of Patent: August 20, 2002
    Assignee: Aventis Pasteur Limited
    Inventors: Lisa E. Myers, Anthony B. Schryvers, Robin E. Harkness, Sheena M. Loosmore, Run-Pan Du, Yan-Ping Yang, Michel H. Klein
  • Publication number: 20020068070
    Abstract: An isolated and purified outer membrane protein of a Moraxella strain, particularly M. catarrhalis, having a molecular mass of about 200 kDa, is provided. The about 200 kDa outer membrane protein as well as nucleic acid molecules encoding the same are useful in diagnostic applications and immunogenic compositions, particularly for in vivo administration to a host to confer protection against disease caused by a bacterial pathogen that produces the about 200 kDa outer membrane protein or produces a protein capable of inducing antibodies in a host specifically reactive with the about 200 kDa outer membrane protein.
    Type: Application
    Filed: March 26, 1996
    Publication date: June 6, 2002
    Inventors: KEN SASAKI, ROBIN E. HARKNESS, SHEENA M. LOOSMORE, PELE CHONG, MICHEL H. KLEIN
  • Patent number: 6361779
    Abstract: Purified and isolated nucleic acid is provided which encodes a transferrin receptor protein of a strain of Haemophilus or a fragment or an analog of the transferrin receptor protein. The nucleic acid sequence may be used to produce peptides free of contaminants derived from bacteria normally containing the Tbp1 or Tbp2 proteins for purposes of diagnostics and medical treatment. Furthermore, the nucleic acid molecule may be used in the diagnosis of infection. Also provided are recombinant Tbp1 or Tbp2 and methods for purification of the same. Live vectors expressing epitopes of transferrin receptor protein for vaccination are provided.
    Type: Grant
    Filed: May 17, 1996
    Date of Patent: March 26, 2002
    Assignee: Aventis Pasteur Limited
    Inventors: Sheena M. Loosmore, Robin E. Harkness, Anthony B. Schryvers, Pele Chong, Scott Gray-Owen, Yan-Ping Yang, Andrew D. Murdin, Michel H. Klein
  • Patent number: 6358727
    Abstract: Purified and isolated nucleic acid is provided which encodes a transferrin receptor protein of a strain of Haemophilus or a fragment or an analog of the transferrin receptor protein. The nucleic acid sequence may be used to produce peptides free of contaminants derived from bacteria normally containing the Tbp1 or Tbp2 proteins for purposes of diagnostics and medical treatment. Furthermore, the nucleic acid molecule may be used in the diagnosis of infection. Also provided are recombinant Tbpl or Tbp2 and methods for purification of the same. Live vectors expressing epitopes of transferrin receptor protein for vaccination are provided.
    Type: Grant
    Filed: August 5, 1996
    Date of Patent: March 19, 2002
    Assignee: Aventis Pasteur Limited
    Inventors: Sheena M. Loosmore, Robin E. Harkness, Anthony B. Schryvers, Pele Chong, Scott Gray-Owen, Yan-Ping Yang, Andrew D. Murdin, Michel H. Klein
  • Patent number: 6335018
    Abstract: An isolated and purified outer membrane protein of a Moraxella strain, particularly M. catarrhalis, has a molecular mass of about 200 kDa. The about 200 kDa outer membrane protein as well as nucleic acid molecules encoding the same are useful in diagnostic applications and immunogenic compositions, particularly for in vivo administration to a host to confer protection against disease caused by a bacterial pathogen that produces the about 200 kDa outer membrane protein or produces a protein capable of inducing antibodies in a host specifically reactive with the about 200 kDa outer membrane protein.
    Type: Grant
    Filed: May 1, 1995
    Date of Patent: January 1, 2002
    Assignee: Aventis Pasteur Limited
    Inventors: Ken Sasaki, Robin E. Harkness, Michel H. Klein
  • Patent number: 6290970
    Abstract: An isolated and purified non-denatured transferrin receptor protein of a Moraxella strain, particularly M. catarrhalis, has an apparent molecular mass of about 80 to about 90 kDa, as determined by SDS-PAGE. The transferrin receptor protein or a fragment analog thereof is useful in diagnostic applications and immunogenic compositions, particularly for in vivo administration to a host to confer protection against disease caused by a strain of Moraxella.
    Type: Grant
    Filed: October 11, 1995
    Date of Patent: September 18, 2001
    Assignee: Aventis Pasteur Limited
    Inventors: Yan-Ping Yang, Lisa E. Myers, Robin E. Harkness, Michel H. Klein
  • Publication number: 20010014672
    Abstract: An isolated and purified outer membrane protein of a Moraxella strain, particularly M. catarrhalis, having a molecular mass of about 200 kDa, is provided. The about 200 kDa outer membrane protein as well as nucleic acid molecules encoding the same are useful in diagnostic applications and immunogenic compositions, particularly for in vivo administration to a host to confer protection against disease caused by a bacterial pathogen that produces the about 200 kDa outer membrane protein or produces a protein capable of inducing antibodies in a host specifically reactive with the about 200 kDa outer membrane protein.
    Type: Application
    Filed: March 19, 1998
    Publication date: August 16, 2001
    Inventors: KEN SASAKI, ROBIN E. HARKNESS, SHEENA M. LOOSMORE, PELE CHONG, MICHEL H. KLEIN
  • Patent number: 6190668
    Abstract: An isolated and purified non-denatured transferrin receptor protein of a Moraxella strain, particularly M. catarrhalis, has an apparent molecular mass of about 80 to about 90 kDa, as determined by SDS-PAGE. The transferrin receptor protein or a fragment analog thereof is useful in diagnostic applications and immunogenic compositions, particularly for in vivo administration to a host to confer protection against disease caused by a strain of Moraxella. The transferrin receptor protein is isolated from strains of Moraxella catarrhalis by a procedure including extraction of agent soluble proteins of a cell mass produced by cultivating the strain under iron-starved conditions. The transferrin receptor protein is selectively solubilized from the extracted cell mass and purified.
    Type: Grant
    Filed: July 30, 1998
    Date of Patent: February 20, 2001
    Assignee: Connaught Laboratories Limited
    Inventors: Yan-Ping Yang, Lisa E. Myers, Robin E. Harkness, Michel H. Klein
  • Patent number: 6090576
    Abstract: Purified and isolated nucleic acid molecules are provided which encode transferrin receptor proteins of Moraxella, such as M. catarrhalis or a fragment or an analog of the transferrin receptor protein. The nucleic acid sequence may be used to produce recombinant transferrin receptor proteins Tbp1 and Tbp2 of the strain of Moraxella free of other proteins of the Moraxella strain for purposes of diagnostics and medical treatment. Furthermore, the nucleic acid molecule may be used in the diagnosis of infection.
    Type: Grant
    Filed: March 8, 1996
    Date of Patent: July 18, 2000
    Assignee: Connaught Laboratories Limited
    Inventors: Lisa E. Myers, Anthony B. Schryvers, Robin E. Harkness, Sheena M. Loosmore, Run-Pan Du, Yan-Ping Yang, Michel H. Klein
  • Patent number: 5808024
    Abstract: An isolated and purified outer membrane protein of a Moraxella strain, particularly M. catarrhalis, has a molecular mass of about 200 kDa. The about 200 kDa outer membrane protein as well as nucleic acid molecules encoding the same are useful in diagnostic applications and immunogenic compositions, particularly for in vivo administration to a host to confer protection against disease caused by a bacterial pathogen that produces the about 200 kDa outer membrane protein or produces a protein capable of inducing antibodies in a host specifically reactive with the about 200 kDa outer membrane protein.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: September 15, 1998
    Inventors: Ken Sasaki, Robin E. Harkness, Sheena M. Loosmore, Michel H. Klein
  • Patent number: 5075223
    Abstract: The present invention provides a recombinant DNA, wherein it contains DNA sequences coding for the N-terminal membrane-penetrating domain of the E-protein of the phage .phi.X 174 and DNA sequences coding for the C-terminal membrane-penetrating domain of the L-protein of the phage MS2 and the DNA sequences of both phages are connected by a DNA sequence coding for a hydrophilic flexible amino acid sequence.The present invention also provides a process for the production of this recombinant DNA.Furthermore, the present invention provides for the use of the recombinant DNA and of a plasmid containing it for obtaining eukaryotic and prokaryotic metabolic products and gene-technologically produced proteins.
    Type: Grant
    Filed: May 9, 1988
    Date of Patent: December 24, 1991
    Assignee: Boehringer Mannheim GmbH
    Inventors: Werner Lubitz, Robin E. Harkness